Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.
He will head the clinical development of Achillion’s hepatitis C treatments.
More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group
